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Abstract
Acetylcholine (ACh) has been shown to modulate neuronal differentiation during early
development. Both muscarinic and nicotinic acetylcholine receptors (AChRs) regulate a wide
variety of physiological responses, including apoptosis, cellular proliferation and neuronal
differentiation. However, the intracellular mechanisms underlying these effects of AChR signaling
are not fully understood. It is known that activation of AChRs increase cellular proliferation and
neurogenesis and that regulation of intracellular calcium through AChRs may underlie the many
functions of ACh. Intriguingly, activation of diverse signaling molecules such as Ras-mitogen-
activated protein kinase, phosphatidylinositol 3-kinase-Akt, protein kinase C and c-Src is modulated
by AChRs. Here we discuss the roles of ACh in neuronal differentiation, cell proliferation and
apoptosis. We also discuss the pathways involved in these processes, as well as the effects of novel
endogenous AChRs agonists and strategies to enhance neuronal-differentiation of stem and neural
progenitor cells. Further understanding of the intracellular mechanisms underlying AChR signaling
may provide insights for novel therapeutic strategies, as abnormal AChR activity is present in many
diseases.
Introduction
Acetylcholine (ACh) is an ancient signaling molecule, [1]
and is present in both prokaryotes and eukaryotes [2-4].
Although ACh has been extensively studied for its role as
a neurotransmitter, it also has autocrine functions [5] in
diverse cell types. ACh has been shown to promote
cytoskeleton organization, cellular proliferation, differen-
tiation and apoptosis [2-4,6-8] throughout development
[2,3,9]. Intriguingly nAChR signaling pathways have been
preserved throughout evolution [10], suggesting that they
have critical functions. We shall attempt to discuss the
physiology of ACh as well as ACh's relevant downstream
pathways in apoptosis, cell proliferation and neuronal
differentiation of embryonic stem cells.
Interestingly, nicotinic receptors are expressed in undiffer-
entiated and differentiating cells, [8,11-13] suggesting
that ACh-mediated signaling between neuronal and non-
neuronal cells may influence cell fate [8,11,12,14]. Sup-
porting this idea, ACh has been shown to modulate neu-
ronal cell differentiation during development [15,16].
Moreover, transfecting a non-neuronal cell line such as a
neuroblastoma with choline acetyltransferase induces
expression of neuronal markers, muscarinic receptors and
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proliferation [17] and apoptosis [18]. These and other
findings marked the beginning of a new field: the role of
nAChRs in the development and progression of cancer
and in stem cell physiology.
Nicotinic ACh receptors
ACh receptors can be nicotinic (nAChRs), which are ion
channels, or G protein-coupled (GPCR) muscarinic recep-
tors (mAChRs). In the central nervous system, nAChRs
have been shown to regulate diverse processes such as
neurotransmitter release and cellular excitability. Nico-
tinic receptors also influence physiologic processes such
as arousal, sleep, fatigue, anxiety, pain processing, hunger
and various higher cognitive functions. [19-22].
nAChRs structure and function
nAChRs are multisubunit proteins of neuromuscular and
neuronal origins. These receptors form ligand-gated ion
channels that mediate synaptic transmission both in the
neuromuscular junction and between neurons. Since var-
ious neuronal nAChR subunits exist, nAChRs can be
formed by different combinations of subunits. [23]. Nico-
tinic receptors of different compositions exhibit different
specificities for various ligands and are thereby pharmaco-
logically distinguishable. For example, the elapid alpha-
neurotoxins that block activation of nAChRs at the neu-
romuscular junction do not block activation of other neu-
ronal nAChR subtypes [24].
A functional nAChR consists of five subunits which may
be different (certain combinations of α1–9 and β1–4, γ, δ,
ε subunits) or identical (α7–9) i.e. subunits [25]. All sub-
units have a similar structure with one extended extracel-
lular domain (N-terminal), four transmembrane domains
(M1–M4), one intracellular domain of variable length
which joins M3 and M4 domains and one small extracel-
lular C-terminal domain [26]. The binding site for ACh
and other agonists is located on the N-terminal extracellu-
lar domain at the boundary between α and non-α subu-
nits. In heteromeric neuronal receptors the α and β
subunits contribute to the binding site The amino acid
sequence analysis of various subunits shows that nicotinic
receptors can be divided into three sub-classes. The first
family includes α-bungarotoxin-sensitive muscle-type
heteromeric receptors, typically found in skeletal muscle
and fish electrical organs, with (α1)2β1γδ and (α1)2β1γε
pentameric structures in fetal and adult form, respectively.
The second family includes nAChRs consisting of α-bun-
garotoxin-insensitive, heteromeric subunits. These recep-
tors have various combinations of α2, α3, α4 and α6 with
β2, β4, α5 and β3 subunits. The third family includes α-
bungarotoxin-binding nicotinic neuronal receptors con-
sisting of five identical subunits (α7, α8 or α9) [19].
Neuronal nAChRs are expressed in the autonomic nerv-
ous system ganglia, and in the CNS, in post- pre and extra
synaptic locations. The α7 nAChR subtype is highly
expressed in regions of the brain involved in learning and
memory, such as the hippocampus and the neocortex
[27]. This subtype has a particularly high permeability for
calcium ions, increases glutamatergic neurotransmission,
and modulates neuronal plasticity by influencing the
growth of axons [28].
Studies on the structure, functions and pharmacology of
nAChRs neuronal receptors are necessary because these
receptors are involved in a large number of nervous sys-
tem diseases (for review see Clementi and Adlkofer Spe-
cial Issue on "nicotinic neuronal receptors" 2000).
Muscarinic ACh receptors
mAChRs structure and function
Muscarinic receptors are members of the G Protein-cou-
pled receptors (GPCRs), and are composed of a family of
five receptor subtypes (M1, M2, M3, M4 and M5). These
receptors are widely distributed on multiple organs and
tissues and are critical to the maintenance of central and
peripheral cholinergic neurotransmission. The distribu-
tion of these receptor subtypes in the brain and other
organs has been extensively studied. M1 is the predomi-
nant subtype found in the cerebral cortex and is involved
in the control of cognitive functions. M2 is the main sub-
type in the heart and is believed to play a role in the con-
trol of heart rate. M3 is involved in gastrointestinal and
urinary tract functioning as well as sweating. M4 is present
in the brain and may have a role in locomotion. Lastly,
M5, also present in the brain, modulates certain functions
of the central nervous system associated with the
dopaminergic system, such as dopamine release in the
nucleus accumbens following mesopontine stimulation
in mice [29]. The M5 subtype is also important for brain-
stimulation reward [30], opiate reward [31], latent inhibi-
tion learning and amphetamine-induced locomotion [32-
34].
As mAChRs are involved in such a wide array of processes,
it is not surprising that muscarinic signaling has been
shown to be abnormal in many diseases, such as overac-
tive bladder [35,36], chronic obstructive pulmonary dis-
ease [36,37], neurodegenerative disease as Alzheimer's
disease [38], dementia [39], Sjogren's disease [40], vascu-
lar dementia [41] and others. Consequently, there is con-
siderable interest in finding pharmacological agents to
selectively modulate each receptor subtype. Agonists such
as muscarine and pilocarpine and antagonists such as
atropine have been known for over a century; however,
these drugs do not target specific subtypes. Unfortunately,
little progress has been made in the discovery of subtype-Page 2 of 20
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cific functions of individual receptor subtypes. The clini-
cal utility of classic muscarinic antagonists such as
atropine is limited due to the high incidence of both
peripheral and central adverse effects such as tachycardia,
blurred vision, dryness of mouth, constipation, dementia,
etc. Atropine derivatives such as ipratropium bromide are
better tolerated but most of them lack of selectivity for
specific muscarinic receptor subtypes. [42-44]. Thus, the
search for subtype selective muscarinic drugs remains an
active area of research.
Muscarinic subtypes are coupled to different GPCRs, lead-
ing to activation of distinct downstream pathways. M1,
M3 e M5 are G-protein coupled receptors (subunit α of
the Gq/11 family), while M2 and M4 subtypes are coupled
to the α subunit of Gi and Go. Consequently different sec-
ond messenger dependent-pathways being activated by
each muscarinic subtype. For example, phospholipase Cβ
(PLC) is activated by M1, M3 and M5, while adenilate
cyclase is activated by M2 and M4 subtypes [45]. Processes
modulated by pathways involving these G-proteins
include smooth muscle contraction (through M2 and M3
receptors), stimulation of glandular secretion (M3 recep-
tors) and inhibition of cardiac voltage-dependent calcium
channels (M2 subtypes) [45].
Expression and function of n- and mAChRs in 
embryonic cells
ACh [46] is present in the brain prior to axonogenesis and
synaptogenesis, suggesting that it may mediate non-classi-
cal signaling. Furthermore, muscarinic receptors are
widely expressed in embryonic cells [8,13,47-54], and
have been shown to regulate neuronal cell proliferation
and differentiation [47,50,51]. In neuronal progenitor
cells, muscarinic receptor expression also occurs prior to
the onset of synaptogenesis and neurotransmission
[9,55], indicating that ACh may act via a local autocrine
loop in the embryo. In early development, M2 receptors
are expressed in the dorsal root ganglia neurons, as well as
in non-neural cells such as Schwann cells, where they con-
trol sensory neuronal differentiation and axonal growth
[56]. Intriguingly, muscarinic receptors are also expressed
in primary and metastatic tumor cells in which ACh also
acts in an autocrine fashion [57]. As discussed above,
expression of muscarinic receptors is an embryonic trait.
The expression of these receptors in tumor cells [8,13,58-
63] likely arises from reactivation of embryonic genes dur-
ing malignant growth [52]. Proliferation due to mAChR
activation has been reported in many tumor cells. For
example, activation of muscarinic M1, M3 or M5 mus-
carinic receptors (but not M2 or M4 receptors) induces
foci of transformation in 3T3 cells [64,65]. Furthermore,
activation of the Gqα11-coupled muscarinic receptors in
various cell lines [59,66,67] or the α7 nicotinic subtype in
P19 embryonic carcinoma cells [13,68,69] induces
growth and proliferation. These effects of muscarinic
receptor activation depend on the cellular phenotype
[70,71]. Activation of M3 induces proliferation in human
colon cancer cell lines and prostate carcinoma cells [72].
In contrast, activation of endogenous M3 inhibits DNA
synthesis in several small cell lung carcinoma cell lines
[72]. These contradictory responses also occur in cells
transfected with mAChRs, as transfected M3 mAChRs has
been reported to both inhibit and stimulate proliferation
[73-75]. In cells deprived of trophic factors, muscarinic
M3 receptor activation elicits anti-proliferative signals via
activation of the small GTP-binding protein, Rac1
[72,76,77]. However, muscarinic agonists can also inhibit
apoptosis. Pretreatment of tumor cell lines with mus-
carinic agonists inhibits apoptosis induced by DNA dam-
age [78-81]. Moreover, agonists for M1, M3 and M5
subtypes showed a protective response against apoptosis
in Chinese hamster ovary cells transfected with these mus-
carinic receptors [82]. This effect occurs via a mechanism
independent of Ca2+/PLC signaling that may involve
upregulation of the anti-apoptopic protein Bcl-2 [6,83]. It
is unclear whether muscarinic receptor activation is
related to tumor growth and stem cell proliferation [8,84-
87]. In addition to morphogenesis, non-neuronal mus-
carinic receptors also control cell migration, as M3, M4
and M5 subtypes were shown to control cell migration by
facilitating fibronectin-induced movement [58,88-90].
Contraction and aggregation of cells in embryonic tissue
is also induced by muscarinic receptor activation [91]. In
this way, mAChRs could modulate cellular movement
during morphogenesis [92,93].
Apoptotic signaling pathways
Apoptotic pathways associated with mAChRs
Many G-protein-coupled receptors protect cells from
apoptosis induced by growth factors, DNA damage or cel-
lular stress. Among those receptors, mAChRs have been
shown to be protective in many cell lines and primary cell
cultures [8,78-80,94,95]. These reports raise the possibil-
ity that damage to cholinergic pathways might contribute
to the development of neurodegenerative disorders, such
as Alzheimer and Huntington. In some neurodegenerative
disorders losses of neuronal survival stimuli occur, lead-
ing to cell death. It is known that mAChRs inhibit apop-
tosis through activation of PI3-kinase
(phosphatidylinositol-3-OH kinase) and its downstream
targets, protein kinase B (PKB)/Akt and MAPK/ERK (Fig-
ure 1) [96]. These kinases activate pro-survival pathways
in diverse cell types [96], including neurons [97,98]. Pre-
vious work [77,80,99-101] has demonstrated that Akt can
be activated effectively through Gq coupled to M1 and M3,
and Gi coupled to M2. Activation of Akt occurs through βγ
complexes and the α, Gαq and Gαi subunits of Gs pro-
teins. The cell survival effects mediated by mAChRs arePage 3 of 20
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ERK pathways [99]. Interestingly, Lindenboim et al., [78],
have demonstrated that the protective effects of ACh in
undifferentiated and neuronal PC12 cells require M1
receptors. In this condition, expression of M2 receptors
decreases DNA synthesis, arresting the cell cycle at S and
G2/M. Furthermore, activation of M1 and M3 receptors
inhibits caspase 2 and 3, and this effect has been shown to
be independent of PI3-kinase and MAPK/ERK pathways
[77,79,102]. Previous reports have described cholinergic
signaling in progenitor and tumoral cells. Gutkind and
collaborators [73] showed how mAChRs exert oncogenic
control in neuronal cell growth by regulating signaling of
extracellular-1/2/MAP. Similar results were also obtained
in non-neuronal cell types [103-105]. Although it is
unclear if mAChR activation is related to oncogenic pro-
gression, there are reports suggesting that inhibition of
mAChRs decrease cell proliferation [8,106]. In line with
these results, previous work showed that apoptosis can be
induced in Chinese hamster ovary cells transfected with
the M3 receptor and exposed to toxic substances [83]. This
effect might be related to caspase action, considering that
M3 receptor activation did not prevent cell death. This
process may be specific for Gq/11 coupled muscarinic sub-
types, specifically M1, M3 and M5 [79,83]. However, the
use of a version of M3 truncated at its carboxyl end
revealed that this protection is not mediated by PLC or by
phosphorylation of its receptor. Moreover, these path-
ways are not involved in activation of ERK and JNK, so
presumably, the anti-apoptotic actions of mAChRs are not
mediated by these proteins, but through its own C termi-
nal domain, which is rich in basic residues [83]. The
mechanism through which mAChRs mediate cell survival
is dependent on transcription of the anti-apoptotic pro-
tein Bcl-2, which can be induced by mAChRs [83]. This
protective feature of mAChRs may be a conserved among
other G-protein coupled receptors.
By targeting two signaling pathways, the MAPK/ERK path-
way [107,108] and the PI3-kinase signaling pathway
[109], it would be possible to gain new insights on the
intracellular signaling pathways through which mAChRs
inhibit apoptosis. It has been suggested that these path-
ways inhibit caspases [77,79,102]. To this end, it was
shown that PKB/Akt, the downstream target of PI3-kinase,
can inhibit both caspase-9, [110-112] and the pro-apop-
totic protein Bad [112-115]. However, PKB/Akt can also
be activated by other pathways. These are mediated by
Diagram depicting apoptotic pathways modulated by nAChRs and mAChRs in neuronal progenitor cellsFigure 1
Diagram depicting apoptotic pathways modulated by nAChRs and mAChRs in neuronal progenitor cells. See 
text for a better description.Page 4 of 20
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kinase and Bad [114,116-119]. Interestingly, inhibitors of
the PI3-kinase or MAPK/ERK pathways could not sup-
press the muscarinic effect on caspases, although all were
able to inhibit the muscarinic-dependent phosphoryla-
tion of PKB/Akt and MAPK/ERK. Furthermore, previous
studies in PC12 cells have shown that these inhibitors
block survival effects and ERK and PI3-kinase signaling
[120,121]. It has been suggested that the MAPK/ERK and
PI3-kinase pathways are not essential for mediating the
muscarinic effect on caspase activity in PC12 cells [79],
but rather that this effect is mediated by an unidentified
pathway. This finding is in line with recent studies show-
ing that in some cases the survival effects of growth factors
and cytokine receptors are mediated by pathways inde-
pendent of both MAPK/ERK and PI3-kinase. For example,
neither the survival effect of nerve growth factor (NGF) on
sympathetic neurons [122] or rat-1/MycER cells trans-
fected with TrkA [123], nor that of granulocyte/macro-
phage colony-stimulating factor on MC cells, is mediated
by the PI3-kinase pathway [124]. Moreover, the MAPK/
ERK and the PI3-kinase pathways are not essential for the
survival effect of NGF on apoptosis induced by ceramide
in PC12 cells [121]. However, the PI3-K/Akt pathway has
an established role in NGF-promoted cell survival [125].
Activation of PI3-K by NGF initiates a cascade involving
Akt, which leads to the phosphorylation and inhibition of
the pro-apoptotic protein Bad and activation of the pro-
survival inhibitor κB kinase α (IKKα) [116,126]. Blockade
of the PI3-K/Akt pathway by a dominant negative Akt
mutant or treatment of cells with PI3-K inhibitors reveal
that activation of this signaling pathway is required for
NGF-promoted cell survival [127]. However, it was shown
that pertussis toxin did not inhibit Akt phosphorylation.
This finding is consistent with the previous observation of
pertussis toxin having a more profound inhibitory effect
during the early phase of NGF-induced Erk1/2 activation
[128]. Upon activation, the TrkA receptor activates the
PI3-K pathway, leading to activation of Akt in sympathetic
neurons [125]. Previous studies have shown that TrkA
forms complexes with GRK2 and GAIP/GIPC (GAIP-inter-
acting protein, C terminus) [128,129], thereby providing
a bridge to link TrkA and G protein signaling pathways.
Furthermore, there is prior evidence pointing to a func-
tional association between pertussis toxin-sensitive G pro-
teins and growth factor receptors such as the insulin
receptor tyrosine kinase [130]. In addition, some pertussis
toxin-sensitive growth factor-induced responses have
been reported. For example, insulin-like growth factor 1
has been shown to activate Gi and release Gβγ subunits
[131,132], while TrkA is able to utilize Gi/o to stimulate
Erk1/2 [128,133]. Increasing evidence shows that GPCRs
often cooperate with RTKs (receptor tyrosine kinases) in
the regulation of numerous signal transduction pathways
[134-136]. More recently, a report has demonstrated that
NGF and lysophosphatidate receptor signaling systems
can interact to promote G protein-mediated activation of
the Erk pathway [133]. These observations are consistent
with the notion that TrkA can utilize pertussis toxin-sensi-
tive Gi/o proteins to activate Akt, thereby inhibiting Bad
and stimulating the NFκB regulator, IKK, via Gαγ activa-
tion [137,138] to allow cell survival through the M3 sub-
type [83,139,140].
One candidate for mediating the muscarinic effect on cas-
pases is sphingosine-1-phosphate, which was shown to
play an important role in the survival effect of NGF on
PC12 cells [141]. Interestingly, sphingosine-1-phosphate
can be induced by the M2 muscarinic receptor [142].
Intriguingly, inhibition of the PI3-kinase pathway par-
tially attenuates the muscarinic survival effect on the via-
bility of the cells but not on caspase inhibition. One
possible explanation is that serum-deprived cells can die
via both caspase-dependent and -independent pathways,
as shown in some apoptotic paradigms such as Bax-
induced cell death in the presence of caspase inhibitors
[143-145]. Despite the fact that the caspase-dependent
pathway seems to play a major role in the death of serum-
deprived PC12 cells, it is possible that once this pathway
is inhibited, the caspase-independent pathway has a
major role. However, one cannot exclude the possibility
that there are unknown caspases which are activated and
involved in apoptosis induced by trophic-factor-depriva-
tion and that these caspases are inhibited by the mus-
carinic receptor in a different mechanism than that used
to inhibit the DEVDase caspases and caspase-2. It was
shown that NGF withdrawal from differentiated PC12
cells induces expression of FasL, which in turn may con-
tribute to the apoptotic process via activation of the CD95
receptor [146,147]. In this case, it is still possible that
muscarinic receptors will inhibit the activation of caspase-
8, the caspase which is directly activated when CD95 is
activated [80,115,148] by a PI3-kinase-dependent mecha-
nism as was shown for CD3 activation in Fas-treated Th2-
type cells [80,115]. In some systems, one signaling path-
way appears to be sufficient for mediating survival
induced by trophic agents such as NGF (PI3-kinase) and
N-acetylcysteine (ERK) [109,120]. However, in other sys-
tems, the survival effect may require the combined action
of several signaling pathways. For example, insulin-like
growth factor-1 inhibited apoptosis in differentiated
PC12 cells requires both PI3-kinase and MAPK/ERK sign-
aling pathways [127,149,150]. It has been suggested that
the muscarinic survival effect could be mediated by the
combined effect of at least two different pathways. One
pathway may lead to caspase inhibition and be independ-
ent of PI3-kinase and ERK signaling. This pathway could
be mediated by the Gi/o-coupled receptors. The other
pathway would act through Gq and may involve the PI3-
kinase pathway, and could promote survival by a mecha-Page 5 of 20
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ated by the Gq-coupled receptors.
Previous reports showed that muscarinic receptor stimula-
tion leads to activation of the Rho family of small G-pro-
teins [151,152]. This pathway can lead to activation of
Rho kinase [153] and is critical for the protective capacity
of muscarinic receptors. It has been demonstrated that
excitatory receptor agonist-induced Rho activation is
Ca2+-dependent [154]. The ability of mAChRs to activate
SRF-mediated gene transcription and the involvement of
G protein subunits in SRF activation were investigated in
Jurkat T cells. It has been shown that Gαq-coupled M1, but
not Gαi/o-coupled M2 receptors can activate SRF through
a RhoA-mediated pathway [73,155]. In contrast, M3
mAChR failed to activate SRF even though M1 and M3 are
thought to induce similar signaling pathways that involve
Gαq/11. Yet, Gαq coupling of both M1 and M3 remained
intact, as revealed by a robust calcium response in Jurkat
T cells. Moreover, use of the chimeric Gα protein con-
struct Gαiq5, which allowed the M2 receptor to signal
along Gαq/11-mediated pathways, restored the Ca2+
response for M2, but not SRF activation. This suggests
either that the activation of SRF through M1 involves a
Gαq/11-independent pathway or that Gαq/11 is insufficient
in Jurkat T cells. The inhibition of M1-SRF signaling by co-
transfection with the Gαq/11 suppressors, RGS2 and RGS4,
indicated that Gαq/11 did play a role in M1-SRF activation,
but it appeared to be insufficient per se. However, an
increase of M1-SRF signaling inhibition was observed
when intracellular calcium was decreased.
Apoptotic pathways associated with nAChRs
Nicotinic receptors are expressed in neural and non-neu-
ronal tissues; however, in the latter their function is not
clear. Although nAChRs are primarily known for their
action as ligand-gated ion channels transducing action
potentials across synapses, they may have other actions as
well, such as cell-to-cell communications in various non-
neuronal tissues controling important cell functions such
as proliferation, adhesion, migration, secretion, survival
and apoptosis in an autocrinal, justacrinal and paracrinal
manner [22]. Interestingly, nicotinic receptors in neurons
protect against cell death in some settings [8,12,68,81]. In
neurons, the α7 nicotinic receptor activates PI3-kinase
through a src-family kinase, activating the anti-apoptotic
kinase AKT [156]. One pathway involved in AKT signaling
involves phosphorylation of the forkhead transcription
factor FKHRL1, causing its retention in the cytoplasm
associated with 14-3-3. This in turn blocks expression of
the apoptotic protein fas [157]. The PI3-kinase/AKT path-
way protects a broad range of neurons against apoptotic
cell death and may block apoptosis triggered by beta-amy-
loid fragments, which contribute to progression of Alzhe-
imer's disease. If so, nicotinic agents may prove useful in
the treatment of this and other neurodegenerative condi-
tions. Interestingly, removal of extracellular Ca2+ sup-
pressed Akt phosphorylation induced by nicotine. It was
shown that an inhibitor of Src tyrosine kinase also
reduced Akt phosphorylation. In addition, PI3-K and Fyn
are physically associated with α7 nicotinic receptors.
Therefore, nicotinic receptor stimulation might lead to
phosphorylation of Akt through Fyn [157-159]. The α7
subtype can mobilize Ca2+ from ryanodine-sensitive intra-
cellular stores and promote cell survival [8,13]. This intra-
cellular Ca2+ mobilization can lead to BDNF-induced
Cdk5-mediated neuroprotection through increased Bcl-2
expression. (Figures 1 and 2). Nicotine has also been
shown to regulate the Bcl-2 family of proteins. For exam-
ple, nicotine induces phosphorylation of Bcl-2 leading to
protection of human small cell lung carcinoma cells
against cisplatin-induced apoptosis [160,161]. Moreover,
nAChRs heterodimers containing α3 and α4 mediate
their apoptotic activity in normal human bronchial epi-
thelial cells through Akt [162]. Lastly nicotine also phos-
phorylates downstream targets of Akt, such as mTOR,
FKHR, elf-4, GSK3b, tuberin and S6K [162].
Nicotine can also promote anti-apoptotic effects through
activation of PKC, PKA and NF-κB, and downregulation
of the tumor suppressor p53 [160,161]. Nicotine-induced
NF-κB phosphorylation promotes the phosphorylation of
the apoptotic protein Bad (Bcl-2 antagonist of cell death),
which becomes inactivated and prevents cell death. Other
pathways underlying the anti-apoptotic effects of nicotine
include the MEK and PI3K pathways [163]. It was previ-
ously shown that ERKs, AKT, and PKA could function as a
Bad Ser112, Ser136, or Ser155 kinase, respectively [164-167].
One interesting study demonstrated that nicotine-
induced Bad phosphorylation is mediated by β-adrenergic
receptors [163] (for a review see [168]), and that nicotine
can also induce phosphorylation of Bax (another Bcl-2
antagonist of cell death) through PKCζ, thereby inactivat-
ing Bax and suppressing cell death [169,170].
The protective effects of nicotine have been studied in
NSCLC and PC12 cell lines, as well as in other experimen-
tal systems [171-176]. Nicotine can protect A549 NSCLC
cells against apoptosis induced by anticancer drugs
through the upregulation of XIAP and survivin in a α3-
nAChR-dependent manner [171]. Furthermore, adminis-
tration of nicotine in the CNS can stimulate release of
neurotransmitters [177,178] and neurotrophic factors,
such as basic fibroblast growth factor (bFGF or FGF-2)
and brain-derived neurotrophic factor (BDNF)[179]. In
addition, nicotine exposure can lead to elevated cellular
cAMP levels [180]. It was demonstrated that nicotine
attenuates both arachidonic acid-induced caspase activa-
tion and apoptosis of spinal cord neurons [181]. How-
ever, controversy exists on the specific nAChR subunitPage 6 of 20
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α7 and the α4β2 subtypes may play the most significant
role in the central nervous system [180,182,183]. Data
from some laboratories indicate that phosphorylation of
ERK1/2 in nicotine-treated neurons can be specifically
prevented by pre-exposure to the α7 blocker α-bugaro-
toxin, but not dihydro-β-erythroidine (an antagonist of
the β2 subunit) [172,178,181], indicating an important
role for the α7 receptor in nicotine-mediated neuropro-
tection. On the other hand, studies in tumor and tumoral
stem cells have implicated the dihydro-β-erythroidine-
sensitive α3 and α4 receptors. This finding implies that
the proliferative effects (mediated by α7 nAChR) and pro-
survival effects (mediated by α3 or α4 nAChR) of nicotine
Diagram depicting proliferative and survival signaling pathways in cellsFigure 2
Diagram depicting proliferative and survival signaling pathways in cells. In vitro, the homomeric and heteromeric 
nAChRs jointly stimulate the indicated signaling cascades. Yellow arrows indicate proliferative pathways triggered by nAChRs. 
This activation triggers the MAP kinase pathway, leading to DNA synthesis. Sustained mitogenic signaling induces to S-phase 
entry. Black arrows indicate nAChR survival and proliferation pathways triggered by intracellular calcium increases involving 
indirect activation of β-adrenergic receptor signaling, which in turn, induces activation of epidermal growth factor (EGF) recep-
tor leading to the cascade indicated by blue arrows. α7 nAChR and heteromeric α-βnAChRs are activated by their agonists. 
Influx of Ca2+ and other cations through the nAChRs and voltage-gated Ca2+ channels trigger the release of adrenaline and 
noradrenalin. Adenylyl cyclase activation downstream of β-adrenergic receptors induce the cyclic AMP-protein kinase A 
(PKA)-CREB (cAMP response element-binding protein) pathway, transactivates epidermal growth factor receptor (EGFR) and 
induces the release of EGF, and perhaps another growth factors. The responsiveness of this pathway is enhanced by α7 
nAChR-mediated activation of Ras through β-arrestin-dependent SRC signaling. In turn, the EGFR activates the Akt pathway 
and its downstream effectors, X-linked inhibitor of apoptosis protein (XIAP)-survivin and nuclear factor-κB (NF-κB).Page 7 of 20
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[8,13,162,171]. These data demonstrate that during dif-
ferentiation there are changes in nAChR activity and func-
tion. This could be due to β-adrenergic receptor activation
through α7 nAChR, which has been found to mediate the
anti-apoptotic effects of nicotine in some cell lines [184-
186] (for a more detailed discussion see [168]). Such dis-
crepancies can be partially explained by the pleiotropic
nature of nAChR subunit inhibitors. It is also possible that
the anti-apoptotic effects of nicotine are mediated by dif-
ferent nAChR subunits in a tissue-specific manner. These
possibilities underscore the need for further studies to
identify the nAChR subunits responsible for the anti-
apoptotic effects of nicotine.
It is known that ERK1/2 signaling can participate in the
neuroprotective effects of nicotine through a variety of dif-
ferent mechanisms. Previous reports showed that ERK2
can increase expression of bcl-2 and inhibit apoptosis
[187]. In addition, the neuroprotective effects of ERK1
and ERK2 may be related to activation of a variety of tran-
scription factors, which in turn can regulate transcription
of neurotrophic factors, leading to overexpression of "sur-
vival" genes and enhanced neuronal viability. Among the
transcription factors that are involved in the ERK-medi-
ated cellular survival are Elk1, nuclear factor-κB (NF-κB),
and cAMP response element (CRE)-binding factor (CREB)
[188-190]. A role for NF-κB in neuronal survival has been
suggested [191]. In addition, recent evidence indicates
that CREB has a crucial role in regulation of cell viability
[192], as it is required to induce transcription of BDNF
[193]. Elk1 functions as a nuclear transcriptional activator
through the interaction with the serum response element
(SRE), which is present in the promoter of many immedi-
ate early genes [194]. Among others, Elk1 is involved in
regulation of expression of FGF-2 [195,196].
Signaling pathways of mAChRs involved in 
proliferation and neuronal differentiation
Previous studies have demonstrated that proliferation and
differentiation of neuronal precursor cells can be modu-
lated by mAChR signaling [8,13,197,198]. The mecha-
nism involved initially amplifies mAChR and nAChR
signals, inducing calcium influx, which in turn activates
MAPK-dependent pathways [8,13,199]. Transient calcium
increases induced by ACh independently of MAPk activa-
tion has been shown to be necessary for differentiation
and proliferation, as muscarinic antagonists and calcium
chelating agents block these effects (Figures 3 and 4)
[8,13].
Activation of M2 and M3 receptors has been shown to
increase proliferation of tumoral cells in a dose-depend-
ent manner. Cellular proliferation induced by the M3 sub-
type is mediated by production of inositol triphosphate,
[8,66] and nitric oxide [for a review see [200]], while the
effects of the M2 subtype were dependent on concomitant
activation of M1, promoting the release of E2 prostaglan-
din and arginase catabolism. These events are related to
tumoral cell growth [66], and inhibition of caspases
[79,83].
In murine mammary adenocarcionoma cells, the M3 sub-
type is the most highly expressed muscarinic receptor.
Stimulation of M3 receptors activates adenilate cyclase,
phospholipase A2 (PLA2), IP3 and diacylglicerol (DAG)
through PLC [201]. Each of these molecules in turn acti-
vates different pathways. DAG activates protein kinase C
(PKC), while IP3 induces release of calcium from intracel-
lular stores. It is known that both pathways regulate
MAPK and ERK signaling. Free intracellular Ca2+ can mod-
ulate MAPK/ERK either through Ca2+-dependent protein
tyrosine kinase (PYK2) [202] or by Ca2+/calmodulin
kinase (Ca2+/CaM) [203]. PKC isoforms are also known to
regulate MAPK/ERK through Raf-1 [204] or through trans-
activation of the epidermal growth factor receptor (EGFR)
mediated by the Src/PYK2 complex (Figures 2 and 3)
[205].
Recent evidence suggests that activation of MAPK/ERK
through GPCRs occurs through PKC-dependent and -
independent mechanisms, depending on the receptor
activated and on the cell type [206,207]. It is known that
activation of MAPK/ERK GPCR agonists mediate cell pro-
liferation [55,208], and that pathways involving choliner-
gic receptors seem to depend on the cell growth [8,74].
Stimulation of mAChRs promotes an increase in [Ca2+]i
and induces phosphorylation of MAPK/ERK in MCF-7
human breast cancer cells [105]. Activation of this path-
way increases protein synthesis and cell proliferation
through MAPK kinase, besides inducing DNA synthesis in
neuronal progenitor cells during early neurogenesis [209].
Inhibition of PLC or incubation of cells in a calcium free
medium did not alter MAPK/ERK phosphorylation; how-
ever, this phosphorylation can also be induced through
treatment with phorbol 12-myristate acetate (PMA), a
PKC activator. Activation of MAPK/ERK was not affected
by PKC modulation or by its inhibition. Interestingly,
phosphorylation of MAPK/ERK by mAChRs could be
blocked by a PKC-ζ (a miroystoilated pseudo substrate of
PKC) inhibitor and by high doses of staurosporine (a rel-
atively non-selective protein kinase inhibitor). This path-
way involves PI3-K and tyrosine kinases, such as Src, and
Erk 1/2 [105,209]. Cells in the neuroepithelial ventricular
zone of the embryonic rat cortex also express the M2
receptor. The presence of M2 induces cell proliferation
and accelerates neuronal differentiation.
Adrenergic receptors can transform fibroblasts when
actively mutated [210]. Interestingly, transformation by
mAChRs was ligand-dependent [211]. Furthermore, somePage 8 of 20
(page number not for citation purposes)
Cell Communication and Signaling 2009, 7:20 http://www.biosignaling.com/content/7/1/20
Page 9 of 20
(page number not for citation purposes)
Muscarinic and nicotinic receptor-coupled signal transduction pathways mediating MAPK activity and proliferationFigure 3
Muscarinic and nicotinic receptor-coupled signal transduction pathways mediating MAPK activity and prolifer-
ation. Both Erk1/2 activity and cell proliferation are activated by cholinergic (ACh) stimulation of mAChRs. ACh binds to M3, 
leading to a Gq-protein-mediated activation of PLC, which hydrolyses PIP2 to IP3 and DAG, subsequently mobilizing Ca2+ from 
organellar stores, leading to activation of PKC. Both ACh-induced MAPK activity and proliferation are reduced by the PKC 
inhibitor H7, indicating that PKC activity appears to be one of the upstream events critical to MAPK activation. mAChR stimu-
lation induces increases in [Ca2+]i via both Ca2+ influx and mobilization from intracellular stores. Muscarinic stimulation of 
MAPK activity and proliferation is prevented both by BAPTA-AM and EGTA, demonstrating that elevation of [Ca2+]i is essen-
tial, and may stimulate Pyk2 phosphorylation and activate the MAPK. Muscarinic stimulation of MAPK activity is effectively elim-
inated by the MAPK kinase (MEK) inhibitor PD98059. M2 and M4 may provide parallel pathways to MAPK activation via 
pertussis toxin-sensitive Gi-proteins and βγ subunits. ERKI/II (MAPK) can serve as a convergence site for multiple extracellular 
signals known to induce plasticity in mature neurons. The best documented activation of the MAPK cascade occurs via ligand 
binding to RTK. Activation of RTK recruits the Shc-Grb2-SOS1 complex, which in turn activates Ras. Ras induces MAPK acti-
vation via an evolutionarily conserved pathway, which includes Raf, MEK (MAPKK), and ERKI/II (MAPK) (MAPK cascade). ERKI/
II is known to have both cytoplasmic and nuclear targets and can translocate to the nucleus to modulate transcription in neu-
rons. The block of proliferation induction by the MEK inhibitor PD98059 suggests that MAPK plays a role in the induction 
phase of proliferation. MAPK can also be activated in neural progenitor cells via nAChRs which increase [Ca2+]i, and may mod-
ulate the MAPK cascade via activation of a Ca2+-dependent tyrosine kinase (PYK2) or calmodulin (CaM).
Cell Communication and Signaling 2009, 7:20 http://www.biosignaling.com/content/7/1/20viruses encode constitutively active GPCRs linked to cell
proliferation (for a review see [212,213]), suggesting that
signals initiated by GPCRs can be mitogenic.
MAPKs target numerous cellular proteins and transcrip-
tion factors involved in cell growth and differentiation
[214-216]. It is known that GPCRs activate MAPK through
the small GTP-binding protein, p21Ras [217]. How
p21Ras is activated is still controversial; however, it is
likely that transactivation of EGFR upon stimulation of
GPCRs participates in p21Ras activation [218,219].
Indeed, several types of GPCRs including thrombin,
endothelin, and angiotensin II receptors have been shown
to transactivate EGFR, leading to MAPK activation
[220,221].
The vast majority of the currently described pathways
leading to ERK stimulation have been considered as lin-
ear. While GPCRs coupled with Gi-protein activate the
p21Ras-ERK pathway through the βγ subunit and PI-3
kinase, GPCRs with Gq-protein activate it in a PKC-
dependent manner [222,223]. However, Blaukat et al.
[223] recently showed that GPCRs mediate ERK activation
through cooperation of Gi and Gq, suggesting that multi-
ple G-proteins could act in concert to attain full activation
of p21Ras-ERK pathway. Muscarinic receptors in many
cells have been shown to activate ERK by carbachol, and
this is not altered by treatment with pertussis toxin, indi-
cating that Gq-, but not Gi-protein, may be involved in
ERK activation [61,224-229]. Muscarinic receptor activa-
tion by carbachol rapidly and transiently stimulates
ERK1/2 phosphorylation in many cells in a time- and
dose-dependent manner [61,226-229], as observed in var-
ious cell lines [230,231]. It was shown that the inhibition
of PLC led to a total blockade of Ca2+ mobilization
induced by AChRs agonists [13,232]. A role of Ca2+ in this
pathway is also supported by the finding that an increase
in intracellular Ca2+ caused by thapsigargin
[8,13,105,233] is sufficient to induce ERK phosphoryla-
tion up to levels similar to those induced by AChRs ago-
nists. The mechanisms by which intracellular Ca2+
stimulates the phosphorylation of ERK1/2 are complex
and appear to be dependent on the nature of mAChR sub-
type coupling to heterotrimeric G proteins. Intracellular
Ca2+ can modulate the MAPK cascade, via activation of the
monomeric G-protein p21ras [234-236], through two con-
vergent mechanisms; one through the calcium-dependent
tyrosine kinase (PYK2) and the other mediated by cal-
modulin [228,231,237]. In T84 colon epithelial cells,
which express endogenous M3 mAChR subtypes,
increases in [Ca2+]i in response to carbachol activate sign-
aling mechanisms involving calmodulin-, PYK2-, and
p60src-mediated transactivation of the EGF receptor [238].
Besides Ca2+, the other downstream pathway induced
Calcium signaling pathways in stem cells and neural progenitor cellsFigure 4
Calcium signaling pathways in stem cells and neural progenitor cells. Left panel represents a embryonic or adult 
stem cells and right panel the neuronal progenitor cells. Ca2+ signaling depends on the increase of the intracellular Ca2+ levels 
[Ca2+]i, derived from extracellular calcium (Ca2+)o sources or intracellular stores of the endoplasmic reticulum (ER Ca2+). It 
can enter through calcium channels operated by voltage (voltage-operated Ca2+ channels, VOCCs) in excitable cells such as 
neurons and muscular cells, or through calcium channels operated by receptors (receptor-operated Ca2+ channels, ROCs) in 
response to neurotransmitters. SOC's (store-operated Ca2+ channels, SOCs), open when internal Ca2+ stores are empty, and 
are generally present in non-excitable cells. Calcium from the ER is released by two types of channels, Inositol 1,4,5-trisphos-
phate (IP3) channels and ryanodine channels. The first is present in both neural progenitor and stem cells, while the latter is 
expressed only in nural progenitor cells. IP3 is generated by the action of the enzyme PLC in phosphatidylinositol 4,5-bisphos-
phate (PIP2). IP3 acts on receptors in the endoplasmic reticulum, promoting the release of Ca2+ from ER stores. IP3PIP2.Page 10 of 20
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was demonstrated that the direct activation of PKC, by the
phorbol ester PMA, was sufficient to increase the phos-
phorylation of ERK1/2 reaching levels similar to those
induced by carbachol in FRT cells [105]. However, the car-
bachol-induced ERK1/2 phosphorylation was not medi-
ated by PKC. These data indicate that the mAChR-induced
ERK phosphorylation is mediated by a Ca2+-dependent
but PKC-independent mechanism.
Although some data suggest that intracellular Ca2+ partly
mediates the activation of ERK1 and ERK2, other intracel-
lular signaling pathways may be involved in the MAPK/
ERK activation in undifferentiated cells. Activation of
MAPK by GPCRs, including mAChRs, involves phosphor-
ylation of one or more proteins, such as p125FAK, p130cas,
or paxillin [239]. Moreover, the Src family of protein tyro-
sine kinases has been implicated in mAChR-induced ERK
activation in different cell lines [240-242]. Further studies
are needed to determine the connection between activa-
tion of these protein tyrosine kinases and the downstream
effects of mAChR after G protein activation.
It has been suggested that carbachol's effects on ERK1 and
ERK2 phosphorylation were probably mediated through
the activation of protein tyrosine kinases. Furthermore, it
has been demonstrated that carbachol-induced ERK acti-
vation is dependent on the activity of cytoplasmatic Src-
like tyrosine kinase family, since pharmacological inhibi-
tion of the Src family of tyrosine kinases with specific PP2
blocks the carbachol-induced MAPK/ERK activation [55].
The Src family of tyrosine kinases has been implicated in
the ERK activation by various GPCRs agonists. Recent data
suggests that activation of Src tyrosine kinases may lead to
the phosphorylation of the adaptor protein Shc and the
recruitment of Grb/Sos complex to the plasma mem-
brane, resulting in the activation of the ERK pathway
[223,243].
Signaling pathways of nAChRs involved in 
proliferation and neuronal differentiation
Previous reports have shown that nAChRs are expressed in
non-neuronal cells within the nervous system [244,245],
embryonic stem cells [8,13], neural stem cells [197], and
embryonic tissues [246].
Microglia express α7 nAChRs [247], and stimulation of
α7 nAChRs promotes anti-inflammatory pathways and
blunts the response of migroglia to lipopolysaccaride
[247], suggesting that nAChRs may have a role in control-
ling localized brain inflammation. Nicotinic receptors are
also expressed on O2A oligodendrocyte precursors, but
are not detectable after induction of differentiation, indi-
cating that nAChR expression is developmentally control-
led in these cells [248]. Although the physiological
functions of nAChRs in O2A oligodendrocyte precursors
are not understood, data suggest that activation of
nAChRs might control migration, survival and differenti-
ation in these cells [248].
It has been found that in non-neuronal tissues nicotine
induces the secretion of growth factors like bFGF, TGF-α,
VEGF, and PDGF [249] Nicotine also upregulates expres-
sion of the calpain family of proteins [250] as well as
COX-2 and VEGFR-2 [251], activating the Raf/MAPK
kinase/ERK pathway [252]. Since nAChRs do not have
intrinsic tyrosine kinase activity [22], the molecular mech-
anisms underlying its effects on proliferation remain
unclear. It was demonstrated that nicotine-mediated
induction of cell proliferation involves recruitment of β-
arrestin, which facilitates the activation of Src. This in turn
leads to binding of Raf-1 kinase to Rb, leading to cell cycle
entry [253]. Dasgupta and coworkers demonstrated that
human non-small cell lung cancer (NSCLC) tumor tissues
had high levels of Rb-Raf-1 complexes in tumors relative
to adjacent normal lung tissue, suggesting that perhaps
the Rb-Raf-1 pathway contributes to the genesis of these
tumors. Furthermore, chromatin IP (ChIP) analysis of
human NSCLC tumor samples demonstrated increased
recruitment of E2F1 and Raf-1 to proliferative promoters
like cdc6 and cdc25A. These results suggest that binding of
β-arrestin to nAChRs is an early and critical event in the
initiation of nicotine-induced mitogenesis. The subse-
quent steps resemble growth factor-induced cell prolifera-
tion, as they include activation of Src, association of Rb to
Raf-1, inactivation of Rb, and enhanced recruitment of
E2F1 and Raf-1 to promoters of genes that induce prolif-
eration [253]. These events are likely to contribute to the
growth and progression of tumoral cells.
Therapeutic uses of cholinergic receptor 
modulators in stem cell specification
In vivo proliferation, differentiation, and genetic 
modification of neural stem cell progeny
As previously demonstrated [8,13], AChRs have different
roles on proliferation in embryonic and neural stem cells.
In embryonic cells, nAChRs decrease proliferation. Con-
versely, neural stem cells and their progeny can be
induced to proliferate in vivo by administering α7 agonists
[13]. To initiate neuronal differentiation, agonists for the
Gαi-coupled mAChRs, such as the M2 subtype, could be
used for treatment. These pharmacological agents include
any substance that acts through AChR activation or
through pathways activated by them. The examples
described here to modulate proliferation, differentiation,
and genetic modification of neural stem cells in vitro can
be adapted to in vivo techniques. Such in vivo manipula-
tion and modification of these cells allows cells lost due
to injury or disease to be endogenously replaced. This
would abolish the need for transplanting foreign cells intoPage 11 of 20
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cally engineered in vivo so that they express various bio-
logical agents useful in the treatment of neurological
disorders. However, fine control of muscarinic signaling
requires compounds that selectively modulate specific
muscarinic receptor subtypes. Unfortunately, such drugs
have not been discovered yet. M1 muscarinic agonists
such as arecoline have also been found to be weak ago-
nists of M2 and M3 subtypes, and are not very effective in
treating cognitive impairment, most likely because of
dose-limiting side effects [254,255]. Selective muscarinic
agonists for M5 and M2 subtypes could be used both as
pharmacological tools and as therapeutic agents [8], as
M5 and M2 mediate most of the muscarinic [Ca2+]i-
response and seem to control proliferation and differenti-
ation induction, respectively.
Treatment with nicotinic receptor agonists also has thera-
peutic potential, similarly to muscarinic agonists. How-
ever, nAChR agonists which bind the same site as ACh are
not a viable solution, for ACh not only activates, but also
blocks receptor activity through desensitization [256] and
uncompetitive blockade [for review see [257]]. Further-
more, prolonged activation appears to induce a long-last-
ing inactivation. Therefore, agonists of ACh may reduce or
enhance receptor activation. In nAChRs, desensitization
generally limits the duration of current during agonist
application [258]. However, positive allosteric modula-
tors can enhance the efficacy of agonists at nicotinic recep-
tors. It is believed that such compounds would be useful
for treatment of conditions associated with decreased nic-
otinic transmission. In a therapeutic setting, these com-
pounds could restore normal interneuronal
communication without affecting the temporal profile of
activation. In addition, they would not produce long-term
inactivation, contrary to prolonged application of an ago-
nist.
A naturally existing allosteric modulator of nicotinic
transmission is the CGRP (Calcitonin Gene Related Pep-
tide) neuropeptide [259,260]. Previous reports show that
CGRP blocks nAChRs competitively. It is noteworthy to
point out that this effect is not mediated by conventional
G-protein-coupling [261], as it was demonstrated that this
peptide's activity is contained within the 1–7 N-terminal
fragment. Similarly to the native CGRP, CGRP 1–7 shows
a rapidly developing, competitive antagonism which is
readily reversible after washout [261]. Intriguingly, some
CGRP fragments quickly and reversibly enhance
responses mediated by the activation of native neuronal
nAChRs [262]. Mutant versions of the CGRP peptide frag-
ment can be used as neuronal nAChRs enhancers, as in
the absence of nAChR activation these peptides were inac-
tive [262].
The CGRP 1–6 peptide did not modify the muscle-type
nicotinic receptor responses, indicating its selectivity for
neuronal receptors. This finding suggests that certain pep-
tide derivatives shorter than CGRP 1–7 exert an unusual
action, involving an apparently competitive modulation
of the agonist-binding site. CGRP 1–6 and its derivatives
may be used for the treatment of symptoms of neurologi-
cal diseases associated with functional deficits of nAChRs
and may be used as stem cell neuronal differentiation
enhancers.
Interestingly, nicotine has been shown to protect cells
from apoptosis induced by anticancer drugs. The acquisi-
tion of drug resistance is a considerable challenge in can-
cer therapy, and nAChR antagonists could be potentially
used in combination with established chemotherapeutic
drugs to enhance the therapeutic response to chemother-
apy. The bioactivity of nAChR antagonists, however, has
yet to be tested in animal models. Carefully designed ani-
mal studies are essential to investigate the potential side
effects of nAChR antagonists on the brain, central nervous
system, immune cells and muscle cells, all of which
express high levels of nicotinic receptors.
The study of the roles of nAChRs in development and pro-
gression of cancer and stem cells differentiation provides
novel opportunities for the prevention and therapy of
cancer and degenerative disorders. However, it is impor-
tant to consider that vital cell and organ functions are reg-
ulated by these receptors. Antagonists for α7 nAChR may
successfully block cancer cells and promote proliferation
of stem cells without cytotoxicity to normal control cells
in vitro, but in vivo it would induce adverse effects on the
control of inflammatory reactions and the regulation of
respiratory and cardiovascular functions, and may also
lead to psychiatric symptoms [22,168,263].
Blockers of Ca2+ channels are known for their anti-prolif-
erative properties and might be an alternative because
they can desensitize the hyperactive α7 nAChR (Figure 1).
However, experimental findings appear to be divergent
and depend on the cell type and mode of administration
used. Among the calcium channel inhibitors, L- and T-
type calcium blockers, were reported to inhibit neuronal
differentiation [12,264-266], but have limited effect on
other cell types. Mibefradil, a selective blocker of T-type
channels, has significant anti-proliferative action in vari-
ous cell types in vitro as well as in vivo [267,268]. The non-
selective calcium blocker amlodipine is also a very effec-
tive protector of neuronal cells [269-271]. Calcium chan-
nel blockers induce a rapid decrease in intracellular Ca2+,
even in cells lacking depolarization-induced calcium flux
[272,273]. These observations suggest that amlodipine
inhibits cell proliferation through intracellular signalingPage 12 of 20
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channels.
Another possible pharmacological treatment is the use of
SluRP1, a drug that reduces the responsiveness of
α7nAChR to agonists. SluRP1 may have an effect similar
to that of voltage-gated Ca2+ channels blockers [274].
However, any attempt to prevent or treat cancer by target-
ing nAChRs must be based on the identification of molec-
ular markers. The goal of this strategy is the restoration of
balance between stimulatory and inhibitory signaling and
not complete blockade of a given pathway.
Nicotinic signaling in non-neuronal cells has huge impli-
cations for cell fate and survival. Research in nAChR sign-
aling networks will be especially relevant to stem cell
production in a large scale and cancer treatment. Future
studies will need to define both the function of different
nAChR subtypes in non-neuronal cells and the down-
stream signaling pathways that underlie the proliferative
and anti-apoptotic activities of nicotine.
Similarly to nicotinic signaling, the mechanisms that
underlie the pro-mitogenic effects of muscarinic receptor
stimulation have not yet been studied in detail. However,
several intracellular signaling pathways that regulate the
synergistic mitogenic interaction of other GPCR agonists
with growth factors in neural progenitor cells have been
identified (Figures 1 and 3). These pathways are not the
same for every GPCR agonist The GPCRs M1 and M3
increase EGF-induced proliferation through a pathway
involving Gβγ, phosphatidylinositol-3-kinase, Akt and
PKC [105,238]. Muscarinic stimulation of MAPK activity
and proliferation is prevented both by the intracellular
Ca2+ chelator BAPTA-AM and by a reduction in extracellu-
lar Ca2+ with EGTA. This suggests that increases in intrac-
ellular calcium are essential, and may stimulate Pyk2
phosphorylation and then activate the MAPK signaling
pathway [238]. PKC also regulates p42/p44 MAP kinase
activation by muscarinic receptor agonists in neuronal
progenitor cells [55].
Concluding remarks
There is a growing body of evidence indicating that nico-
tinic and muscarinic receptors play important roles in
stem cell differentiation and physiology. The disruption
of developmental patterns and of normal function is often
correlated with pathological conditions. Therefore, the
controlled manipulation of ACh function may lead to
novel therapies. Strikingly, studies have revealed that
drugs currently used to treat disorders such as Alzheimer's
disease and depression, increase adult neurogenesis,
which may be the mechanism mediating the activity of
these drugs. However, some of these studies are controver-
sial, and remain to be confirmed. Hence, the role of neu-
rogenesis in treating central nervous system disorders, as
well as the effects of drugs on embryonic and adult stem
cells' neuronal differentiation remain areas of active
research. Discriminating specific contributions of nAChR
and mAChR signaling for the control of phenotypic fea-
tures as specialized structural and functional behaviors is
a great challenge and has undeniable potential regarding
future applications.
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